NCT05067894View on ClinicalTrials.gov

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

April 11, 2022

Study Completion Date

August 6, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

SARS-CoV-2 Protein Subunit Recombinant Vaccine

intramuscular injection

BIOLOGICAL

SARS-CoV-2 Inactivated Vaccine

intramuscular injection

Trial Locations (1)

Unknown

Fakultas Kedokteran Universitas Indonesia, Jakarta

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Fakultas Kedokteran Universitas Indonesia

OTHER

collaborator

National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

OTHER

lead

PT Bio Farma

INDUSTRY